Zymeworks ZYME Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Research and development collaborations by Product | |||||
| Development support payments | $5.62M— | —— | $52.62M+155% | $20.67M+264% | |
| Drug supply for ongoing studies | $6.55M-65.9% | $19.23M-25.1% | $25.66M+611% | $3.61M— | |
| Other drug supply | $2.23M-85.6% | $15.46M+15.8% | $13.35M+6,781% | $194K— | |
| Royalties | $2.48M+2,381% | $100K— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zymeworks break its business down?
- Zymeworks (ZYME) reports research and development collaborations by product across 5 parts — Development support payments, Drug supply for ongoing studies, Milestone revenue, Other drug supply and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Zymeworks's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zymeworks's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.